Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by Snowballgrowthon Sep 07, 2020 7:40pm
108 Views
Post# 31518569

RE:RE:RE:RE:Interesting Situation ...

RE:RE:RE:RE:Interesting Situation ...
drippingsnot wrote: That's what I'm thinking Kentucky ... at a 17% interest rate, Moksha8 is desperate.

Keep in mind too - the owners of Moksha8 is an equity firm and they should have access to cash.  Doesn't seem to be the case, or they know the cash alone won't do it ... the business needs GUD's help.

Moksha8 CEO Joel Barlan said: “We are thrilled with this partnership. Moksha8 is entering a new era of growth, supported by both a talented team and significant product launches. Knight’s partnership provides the fuel for the expansion of our strategy to the next level.”

Moksha8’s majority shareholder, Montreux Equity Partners’ founder Daniel K Turner III said: “We view the Board collaboration as a crucial part of the agreement.

“Combining Moksha8’s deep market and commercial knowledge with Knight’s exceptional track record as a licensee and acquirer boosts Moksha8’s capabilities to new levels”.

Maybe Montreux realizes the past mistake they made in getting into Moksha8 and they need GUD to help them to get out of the mess.  Converting Moksha8 shares into GUD ownership might prove a better direction for Montreux's equity investors (longer-term). 

And now that Knight has grown into a LATAM force, Moksha8 might be worried about beeing steamrolled and prefer a combination.




Did you see Knight's observers on the board ? I didn't

https://www.moksha8.com/board-of-directors.html

https://www.globenewswire.com/news-release/2019/02/18/1733742/0/en/Knight-Signs-GUD-Bueno-Latin-American-Strategic-Funding-Deal-with-Moksha8.html

<< Previous
Bullboard Posts
Next >>